StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Tuesday. The firm set a “sell” rating on the stock.

Separately, Piper Sandler restated an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Stock Down 3.3 %

NSPR stock opened at $2.92 on Tuesday. The business has a 50 day moving average price of $2.58 and a 200 day moving average price of $2.63. The stock has a market cap of $76.15 million, a price-to-earnings ratio of -3.63 and a beta of 0.93. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.42.

InspireMD (NYSE:NSPR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. The business had revenue of $1.81 million during the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same quarter in the previous year, the firm earned ($0.15) EPS. As a group, sell-side analysts anticipate that InspireMD will post -0.79 EPS for the current year.

Hedge Funds Weigh In On InspireMD

Institutional investors have recently modified their holdings of the business. Parkman Healthcare Partners LLC acquired a new stake in InspireMD during the 3rd quarter worth $279,000. Affiance Financial LLC acquired a new stake in shares of InspireMD during the third quarter worth about $492,000. Finally, Rosalind Advisors Inc. grew its holdings in shares of InspireMD by 266.4% during the second quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock worth $6,272,000 after buying an additional 1,827,579 shares during the last quarter. 44.78% of the stock is owned by institutional investors and hedge funds.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.